These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28458650)

  • 21. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
    Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
    J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.
    Godtfredsen NS; Jørgensen DV; Marsaa K; Ulrik CS; Andersen O; Eugen-Olsen J; Rasmussen LJH
    Respir Res; 2018 May; 19(1):97. PubMed ID: 29783959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
    Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
    J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. suPAR as a marker of infection in acute kidney injury - a prospective observational study.
    Hall A; Crichton S; Varrier M; Bear DE; Ostermann M
    BMC Nephrol; 2018 Aug; 19(1):191. PubMed ID: 30071826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Use of somatosensory evoked potentials for preoperative assessment in patients with severe aneurysmal subarachnoid hemorrhage before surgical or interventional treatment: a prospective observational cohort study].
    Zhao J; Luo X; Zhang Z; Chen K; Shi G; Zhou J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Mar; 30(3):251-256. PubMed ID: 29519285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of excellent functional outcome in aneurysmal subarachnoid hemorrhage.
    Pegoli M; Mandrekar J; Rabinstein AA; Lanzino G
    J Neurosurg; 2015 Feb; 122(2):414-8. PubMed ID: 25495745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.
    Mossanen JC; Pracht J; Jansen TU; Buendgens L; Stoppe C; Goetzenich A; Struck J; Autschbach R; Marx G; Tacke F
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroglobin as a Novel Biomarker for Predicting Poor Outcomes in Aneurysmal Subarachnoid Hemorrhage.
    Cai H; Zheng S; Cai B; Yao P; Ding C; Chen F; Kang D
    World Neurosurg; 2018 Aug; 116():e258-e265. PubMed ID: 29738858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative and postoperative predictors of long-term outcome after endovascular treatment of poor-grade aneurysmal subarachnoid hemorrhage.
    Zhao B; Yang H; Zheng K; Li Z; Xiong Y; Tan X; Zhong M;
    J Neurosurg; 2017 Jun; 126(6):1764-1771. PubMed ID: 27367238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
    Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
    Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis.
    Nikkola A; Aittoniemi J; Huttunen R; Rajala L; Nordback I; Sand J; Laukkarinen J
    Pancreas; 2017 Jan; 46(1):77-82. PubMed ID: 27841794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
    Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E
    J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain plasticity and neuroinflammatory protein biomarkers with circulating MicroRNAs as predictors of acute brain injury outcome - A prospective cohort study.
    Sajanti A; Li Y; Hellström S; Cao Y; Girard R; Umemori J; Frantzén J; Koskimäki F; Lyne SB; Falter J; Rantamäki T; Takala R; Posti JP; Roine S; Kolehmainen S; Srinath A; Jänkälä M; Puolitaival J; Rahi M; Rinne J; Castrén E; Koskimäki J
    J Neurol Sci; 2024 Sep; 464():123169. PubMed ID: 39126731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity.
    Saylam Kurtipek G; Kesli R; Tuncez Akyurek F; Akyurek F; Ataseven A; Terzi Y
    Int J Rheum Dis; 2018 Apr; 21(4):866-870. PubMed ID: 27171829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
    Riisbro R; Christensen IJ; Nielsen HJ; Brünner N; Nilbert M; Fernebro E
    Int J Biol Markers; 2005; 20(2):93-102. PubMed ID: 16011039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.
    Haupt TH; Kallemose T; Ladelund S; Rasmussen LJ; Thorball CW; Andersen O; Pisinger C; Eugen-Olsen J
    Biomark Insights; 2014; 9():91-100. PubMed ID: 25574132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
    Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
    Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
    Sörensen NA; Nikorowitsch J; Neumann JT; Rübsamen N; Goßling A; Hartikainen TS; Blankenberg S; Westermann D; Zeller T; Karakas M
    Clin Res Cardiol; 2019 Dec; 108(12):1386-1393. PubMed ID: 30989318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.